Share: 
Status: 
Expired
Rating: 
No votes yet
0

Managing Diabetes in Special Populations

Course description

Managing Type 2 Diabetes in Special Populations: Patient-Centered Treatment to Improve Outcomes 

General Objective

To enable primary care clinicians to integrate emerging antihyperglycemic agents into culturally-competent, patient-centered treatment strategies in the management of type 2 diabetes.

Target audience: 

Family physicians, other primary care physicians, and those with an interested in diabetes care.

Learning objectives: 
  • Employ culturally competent, patient-centered treatment strategies to manage type 2 diabetes in elderly, overweight/obese, or Latino/Latina patients.
  • ​Employ strategies to overcome barriers that traditionally inhibit the initiation of care in these populations.
  • Design safe and effective treatment strategies that are tailored to the individual needs of patients in these populations.
  • Integrate emerging antihyperglycemic agents into patient-centered type 2 diabetes management plans for persons in these populations.
Credits & accreditation
  • 2.00 AAFP
  • 2.00 Attendance
Faculty & disclosure

Disclosures of Relevant Financial Relationships

In accordance with the ACCME Standards for Commercial Support and with the policies of the American Academy of Family Physicians, NJAFP policy requires that all persons that affect the content of this CME activity disclose to the CME providers financial relationships they or their spouse/significant other have with either the commercial supporter of this activity or with the manufacturers of any products they are referencing in this enduring material. The following individuals have provided disclosure information:

Planners

NameManufacturer with whome there is a Financial RelationshipType of Relationship
Theresa J. Barrett, PhDNANo Relationships
Jack DouglassNANo Relationships

Charles A. Goldthwaite, Jr., PhD.

NANo Relationships

Faculty

FacultyPositionManufacturer with whom there is a Financial RelationshipType of Relationship
Ildiko Lingvay, MD, MPH, MSCSAssociate Professor; Department of Internal Medicine/ Division of Endocrinology. Department of Clinical Sciences; University of Texas Southwestern Medical Center; Dallas, TX

AstraZeneca
Janssen Pharmaceuticals

Paid Consultant

Jerry McCauley, MD, MPH, FACPRobert Capizzi Professor of Medicine; Director, Division of Nephrology Sidney Kimmel Medical College Thomas Jefferson University Hospital Philadelphia, PANANo Relationships
Everett Schlam, MD Assistant Director
Mountainside Family Practice Residency Program; Clinical Assistant Professor, Department of Family Medicine UMDNJ – New Jersey Medical School, Verona, NJ
GaldermaPaid Consultant
Penny Tenzer, MD, FAAFPProfessor of Clinical Family Medicine
Vice Chair of Academic Affairs
Director of CME and Medical Education; Chief of Service, Family Medicine, University of Miami Hospital; University of Miami Miller School of Medicine; Miami, FL

AstraZeneca
Exact Science

Advisory Board


 

REVIEWER

Lauren Curruth, MD the reviewer has no relevant financial relationships.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT

This program is supported by an educational grant from Janssen pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

DATE OF RELEASE AND TERMINATION DATE

The Date of Release for this activity is: June 1, 2016

The Terminate Date for this activity is: May 31, 2017

Additional information
Required hardware / software: 

Adobe Reader

Course summary
Available credit: 
  • 2.00 AAFP
  • 2.00 Attendance
Course opens: 
06/01/2016
Course expires: 
05/31/2017
Please login or register to take this course.